Novo CEO spies new pricing model in EU

CEO of Novo Nordisk Lars Fruergaard Jørgensen will be the pharmaceutical industry’s ear to the ground as the industry’s fundamental EU framework is revised. He tells MedWatch about the strategy, which he hopes will bolster European life science, and a new pricing mechanism he hopes will ensure better market access.

CEO of Novo Nordisk Lars Fruergaard Jørgensen sees a need to challenge current technological evaluations a pricing mechanisms if the European market is to become attractive once again, and has spotted an opportunity within the EU | Photo: Valdemar Ren
by peter thomsen, eu correspondent for watch medier, translated by catherine brett & daniel pedersen

BRUSSELS – At first, the signs were small, Lars Fruergaard Jørgensen remembers.

New products went from being rolled out across Europe to only finding their way to a small selection of countries. This was the first indication that the EU’s pharmaceutical industry was beginning to lag behind its competition.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today